Dr. Robert Johnson -- Pharmaceutical Payment Report

This page provides a comprehensive transparency report for Dr. Robert Johnson, a Internal Medicine physician based in City, MO. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Robert Johnson has received $106,752.46 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.

Physician Profile

The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.

Payment Summary

Dr. Robert Johnson has received a total of $106,752.46 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $106,752.46 per transaction.

Payment Breakdown by Category

The following table shows how Dr. Robert Johnson's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.

Payment CategoryAmountDescription
Research Funding$106,752.46Clinical trial funding, research grants, and study-related payments

The largest payment category for Dr. Robert Johnson is Research Funding, accounting for 100% ($106,752.46) of total pharmaceutical payments received. This suggests active involvement in clinical trials and pharmaceutical research programs.

Pharmaceutical Company Relationships

The following pharmaceutical and medical device companies have made payments to Dr. Robert Johnson. Click on any company name to view their full physician payment profile and spending patterns.

CompanyTotal PaidTransactions
Pfizer Inc$106,752.461

Dr. Robert Johnson has a financial relationship with Pfizer Inc, receiving $106,752.46 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.

AI Transparency Analysis

The following analysis was generated by artificial intelligence based on Dr. Robert Johnson's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.

Robert Johnson has received $106.8K across 1 pharmaceutical payments as a Internal Medicine physician in City, MO. Top paying companies include Pfizer Inc ($106.8K). The physician received a single, substantial payment of $106,752 in 2024. This payment was exclusively for research purposes, indicating a focus on clinical trials or studies. The entire amount originated from a single pharmaceutical company, Pfizer Inc., representing 100% of the total payments received.

Patient Guidance: Questions to Ask Your Doctor

If Dr. Robert Johnson is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:

If your doctor is involved in research, it's beneficial to understand the nature of the studies and how they might influence treatment recommendations. Always feel free to ask your doctor directly about their pharmaceutical relationships.

Peer Comparison: How Dr. Robert Johnson Compares to Other Internal Medicine Physicians

For Internal Medicine specialists, this payment is significantly higher than the average, likely due to the specific nature of the research payment.

Recent Payment Records

The following table shows the most recent pharmaceutical industry payments recorded for Dr. Robert Johnson in the CMS Open Payments database. Click on any payment to view the full report.

CompanyAmountTypeDrug/DeviceDateConflict Level
Pfizer Inc$106,752.46researchN/A2024-09-11Not Assessed

Frequently Asked Questions About Dr. Robert Johnson's Pharma Payments

Below are common questions patients ask about physician pharmaceutical payment data.

How much pharma money has Robert Johnson received?

Robert Johnson has received a total of $106.8K across 1 payments from pharmaceutical companies. This data is publicly reported under the CMS Open Payments (Sunshine Act) program.

Is Robert Johnson taking too much pharma money?

Robert Johnson has received $106.8K in pharmaceutical payments. Whether this is "too much" depends on the physician's specialty (Internal Medicine), the types of payments, and how they compare to peers. The largest payment category is research ($106.8K). Payment does not imply wrongdoing, but patients should be aware and can ask their doctor directly.

What pharma companies pay Robert Johnson?

The top pharmaceutical companies paying Robert Johnson are: Pfizer Inc ($106.8K). These payments cover various categories including consulting, meals, speaking fees, and research grants.

What kinds of payments does Robert Johnson receive?

Robert Johnson's payments by type: research: $106.8K. Research payments indicate involvement in clinical studies.

Should I switch doctors because of pharma payments?

Pharma payments alone are not typically reason to switch doctors. Many payments are routine (like meals at educational events) and do not indicate compromised care. Focus on: (1) whether your doctor explains treatment options clearly, (2) whether generic alternatives are discussed, (3) the overall pattern of payments, not individual transactions. If you have concerns, ask your doctor directly.

How do Robert Johnson's payments compare to other Internal Medicine doctors?

To compare, look at the total amount ($106.8K), number of payments (1), and the types of payments received. Internal Medicine physicians may receive different payment amounts depending on subspecialty, geographic location, and academic affiliation. Use CMS Open Payments data to compare across the specialty.

How can I verify Robert Johnson's payment data?

You can verify this data directly through the CMS Open Payments database at openpaymentsdata.cms.gov. Search by physician name or NPI number (1291261523). All data is reported by pharmaceutical companies and verified by CMS. DoctorPharmaData aggregates this public data for easier access.

Do pharma payments affect prescribing quality?

Research published in JAMA Internal Medicine and other peer-reviewed journals shows a statistical association between pharmaceutical payments and prescribing patterns. However, correlation does not equal causation. Many physician-industry interactions are legitimate (research, education, advisory boards). The Sunshine Act was created to promote transparency so patients can make informed decisions.

What stands out about Robert Johnson's pharma payment profile?

The physician's payment profile is highly concentrated, with all funds coming from one company and for one purpose. Robert Johnson has received $106.8K in total pharma payments.

How does Robert Johnson compare to peers in Internal Medicine?

For Internal Medicine specialists, this payment is significantly higher than the average, likely due to the specific nature of the research payment.

Are Robert Johnson's pharma relationships typical for Internal Medicine?

The large single payment suggests involvement in a significant research project or a long-term research agreement.

What should patients of Robert Johnson know about these payments?

If your doctor is involved in research, it's beneficial to understand the nature of the studies and how they might influence treatment recommendations.

What patterns are visible in Robert Johnson's payment history?

The data reflects activity in a single year (2024), providing a limited view of the physician's overall payment history.

Understanding This Doctor Payment Report

This transparency report for Dr. Robert Johnson is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:

About the Physician Payments Sunshine Act

The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.

Under this law, Dr. Robert Johnson's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.

The Open Payments data for Dr. Robert Johnson and all other physicians can be accessed at the official CMS Open Payments website.

Related Resources

Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.